Benzthiazide

Benzthiazide

SCHEMBL26257

NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC12A3

The experimentally established mechanism targets of Benzthiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
CYP3A4 P08684 3/20 0.63
CYP2C9 P11712 3/20 0.63
TSHR P16473 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
KDM4E B2RXH2 2/20 0.63
MEN1 O00255 1/20 0.63
NR1I2 O75469 1/20 0.63
ABCB11 O95342 1/20 0.63
ADRA2A P08913 1/20 0.63
CYP2D6 P10635 1/20 0.63
PKM P14618 1/20 0.63
ADRA2B P18089 1/20 0.63
ADRA2C P18825 1/20 0.63
KMT2A Q03164 1/20 0.63
CYP1A2 P05177 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CA1 P00915 12/20 0.42
CA2 P00918 11/20 0.42
CA12 O43570 10/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzthiazide SCHEMBL345215 0.99 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL7102453 0.99 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL6546528 0.99 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL7217920 0.99 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL9517821 0.99 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL1276519 0.97 ALDH1A1 (0.60) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL23860715 0.95 ALDH1A1 (0.58) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL386685 0.95 ALDH1A1 (0.58) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL386952 0.95 ALDH1A1 (0.58) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2
Benzthiazide SCHEMBL2376967 0.95 ALDH1A1 (0.58) ALDH1A1CYP3A4CYP2C9TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 36582 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090360-A1 FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC. (US) 2026-04-30 WO claimed
US-20260108529-A1 FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC (US) 2026-04-23 US claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
EP-4655398-A1 ARTIFICIAL POLYNUCLEOTIDE MOLECULES FOR ENHANCED STABILITY AND TRANSLATION Eleven Therapeutics Ltd (IL) 2025-12-03 EP claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2025081079-A2 THE METHODS AND COMPOSITIONS OF DONOR DNA MOLECULES THE GENERAL HOSPITAL CORPORATION (US) 2025-04-17 WO claimed
WO-2025072699-A1 AMINOGLYCOSIDES FOR DELIVERY OF AGENTS TO THE KIDNEY JUDO BIO, INC. (US) 2025-04-03 WO claimed
WO-2025072713-A1 POLYMYXINS FOR DELIVERY OF AGENTS TO THE KIDNEY JUDO BIO, INC. (US) 2025-04-03 WO claimed
WO-2025072672-A2 SLC6A19-TARGETING MODULATORY NUCLEIC ACID AGENTS JUDO BIO, INC. (US) 2025-04-03 WO claimed
US-20250066780-A1 OLIGONUCLEOTIDES WITH INTERNUCLEOTIDE LINKAGE MODIFICATIONS FOR KIDNEY TARGETING UNIV MASSACHUSETTS (US) 2025-02-27 US claimed
EP-0046289-A2 Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates MERCK & CO. INC. (US) 1982-02-24 EP claimed
US-4311697-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1982-01-19 US claimed
US-4285947-A DIURETICS, HYPOTENSIVES INTERX RESEARCH CORPORATION (US) 1981-08-25 US claimed
EP-0032725-A1 Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1981-07-29 EP claimed
US-4238485-A 1,2,5-THIADIAZOLE DERIVATIVE, THIAZIDE DIURETIC, HYPOTENSIVE AGENTS MERCK & CO., INC. (US) 1980-12-09 US claimed
US-4217347-A MERCAPTOALKYL ALKANOYLPROLINES AND A DIURETIC E. R. SQUIBB & SONS, INC. (US) 1980-08-12 US claimed
US-4178374-A SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION MERCK & CO., INC. (US) 1979-12-11 US claimed
EP-0001929-A2 Plasmid for transforming bacterial host to render it capable of polypeptide expression GENENTECH, INC. (US) 1979-05-16 EP claimed
EP-0001930-A2 Method for polypeptide production involving expression of a heterologous gene, recombinant microbial cloning vehicle containing said gene and bacterial culture transformed by said cloning vehicle GENENTECH, INC. (US) 1979-05-16 EP claimed
US-4022894-A Stable solution of benzthiazide (3-[benzythiol methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide) suitable for parenteral administration and process of preparation FAINBERG SAMUEL M 1977-05-10 US claimed